Type I surface antigen associated with staphylococcus epidermidis
US5961975A · kind A · utility
8Cited by
5References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 7, 1995 |
| Grant date | Oct 5, 1999 |
| Priority date | — |
| Expiry date | Jun 7, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A process is disclosed for culturing clinical Staphylococcus epidermidis cells that reproducibly enables identification of a limited number of predominant serotypes. Two predominant serotypes common to most clinical cases of S. epidermidis have been identified and are denoted Type I and Type II. A particular polysaccharide surface antigen is associated with each of the Type I and Type II serotypes. The surface antigens can be used to provide active and passive immunization against S. epidermidis infection and to produce a hyperimmune immunoglobulin or antibodies for treatment of S. epidermidis infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.